Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 453

1.

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.

Fidai SS, Sharma AE, Johnson DN, Segal JP, Lastra RR.

Autops Case Rep. 2018 Nov 30;8(4):e2018049. doi: 10.4322/acr.2018.049. eCollection 2018 Oct-Dec.

2.

5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.

Boilève A, Wicker C, Verret B, Leroy F, Malka D, Jozwiak M, Pontoizeau C, Ottolenghi C, De Lonlay P, Ducreux M, Hollebecque A.

Anticancer Drugs. 2019 Mar;30(3):313-317. doi: 10.1097/CAD.0000000000000730.

PMID:
30531368
3.

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM.

Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32022. [Epub ahead of print]

PMID:
30485432
4.

[A Case of Colon Cancer with DPD Deficiency That Showed Severe Myelosuppression by CapeOX Adjuvant Chemotherapy after Colon Resection].

Watanabe H, Arita S, Takeuchi T, Oshima Y, Koike N.

Gan To Kagaku Ryoho. 2018 Nov;45(11):1661-1664. Japanese.

PMID:
30449859
5.

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.

Lunenburg CATC, Henricks LM, Dreussi E, Peters FP, Fiocco M, Meulendijks D, Toffoli G, Guchelaar HJ, Swen JJ, Cecchin E, Schellens JHM, Gelderblom H.

Eur J Cancer. 2018 Nov;104:210-218. doi: 10.1016/j.ejca.2018.07.138. Epub 2018 Oct 23.

PMID:
30361102
6.

Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.

van Kuilenburg ABP, Meijer J, Meinsma R, Pérez-Dueñas B, Alders M, Bhuiyan ZA, Artuch R, Hennekam RCM.

JIMD Rep. 2019;45:65-69. doi: 10.1007/8904_2018_138. Epub 2018 Oct 23.

7.

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene.

García-González X, López-Tarruella S, García MI, González-Haba E, Blanco C, Salvador-Martin S, Jerez Y, Thomas F, Jarama M, Sáez MS, Martín M, López-Fernández LA.

Cancer Manag Res. 2018 Oct 11;10:4517-4522. doi: 10.2147/CMAR.S174470. eCollection 2018.

8.

Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.

Murphy C, Byrne S, Ahmed G, Kenny A, Gallagher J, Harvey H, O'Farrell E, Bird B.

Dose Response. 2018 Oct 1;16(4):1559325818803042. doi: 10.1177/1559325818803042. eCollection 2018 Oct-Dec.

9.

Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer.

Lin K, Jiang H, Zhuang SS, Qin YS, Qiu GD, She YQ, Zheng JT, Chen C, Fang L, Zhang SY.

FASEB J. 2019 Feb;33(2):1972-1988. doi: 10.1096/fj.201800759R. Epub 2018 Sep 18.

PMID:
30226808
10.

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].

Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A.

Bull Cancer. 2018 Sep;105(9):790-803. doi: 10.1016/j.bulcan.2018.06.008. Epub 2018 Aug 10. Review. French.

11.

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening.

Tong CC, Lam CW, Lam KO, Lee VHF, Luk MY.

Front Oncol. 2018 Jul 24;8:279. doi: 10.3389/fonc.2018.00279. eCollection 2018.

12.

Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.

Khushman M, Patel GK, Hosein PJ, Laurini JA, Cameron D, Clarkson DR, Butler TW, Norden CW, Baliem W, Jones V, Bhadkamkar S, Nelson C, Lee F, Singh AP, Taylor WR.

J Gastrointest Oncol. 2018 Jun;9(3):416-424. doi: 10.21037/jgo.2018.02.03.

13.

Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.

Garcia RAG, Saydoff JA, Bamat MK, von Borstel RW.

Toxicol Appl Pharmacol. 2018 Jun 13;353:67-73. doi: 10.1016/j.taap.2018.06.012. [Epub ahead of print]

PMID:
29908244
15.

Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.

Tariq Z, Mudge R, Phillips S.

Am J Ther. 2018 Nov/Dec;25(6):e742-e743. doi: 10.1097/MJT.0000000000000753. No abstract available.

PMID:
29889674
16.

Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.

Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Cowley D, Harris M, van Kuilenburg ABP, Helsby N, George R, Charles BG.

Ther Drug Monit. 2018 Aug;40(4):495-502. doi: 10.1097/FTD.0000000000000532.

PMID:
29846282
17.

Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma.

Gao J, Zhen R, Liao H, Zhuang W, Guo W.

Oncol Lett. 2018 May;15(5):7175-7181. doi: 10.3892/ol.2018.8242. Epub 2018 Mar 12.

18.

Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12.

van Kuilenburg ABP, Tarailo-Graovac M, Meijer J, Drogemoller B, Vockley J, Maurer D, Dobritzsch D, Ross CJ, Wasserman W, Meinsma R, Zoetekouw L, van Karnebeek CDM.

Hum Mutat. 2018 Jul;39(7):947-953. doi: 10.1002/humu.23538. Epub 2018 May 10.

PMID:
29691939
19.

Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.

Jacobs L, van der Vlies E, Ten Bokkel Huinink D, Bloemendal H, Intven M, Smits AB, Weusten BLAM, Siersema PD, van Lelyveld N, Los M.

Clin Colorectal Cancer. 2018 Sep;17(3):179-186. doi: 10.1016/j.clcc.2018.03.004. Epub 2018 Mar 8.

PMID:
29661620
20.

[Requirement of DPD deficiency screening before prescription of fluoropyrimidines].

Penel N.

Bull Cancer. 2018 Apr;105(4):331-332. doi: 10.1016/j.bulcan.2018.03.001. French. No abstract available.

PMID:
29661375

Supplemental Content

Loading ...
Support Center